Hepatotropc effects of glucose-lowering drugs: non-alcoholic fatty liver disease in focus

Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM2) often coexist and share common pathogenic mechanisms& Being components of the metabolic syndrome, these pathologic conditions exacerbate each other’s course, increase the risk of adverse cardiovascular outcomes in comorbid patients. The main focus in the treatment of patients with DM2 and NAFLD is aimed at reducing insulin resistance and slowing down the transition of steatosis and/or steatohepatitis into a more progressive stage. For this aim, a number of hypoglycemic drugs are used in diabetology, which have demonstrated their beneficial effects on the NAFLD. This article presents the results of clinical and experimental studies on the use of the following groups of drugs in patients with NAFLD: biguanides, glucagon-like peptide-1 agonists, type 4 dipeptidylpeptidase inhibitors, thiazolidindiones and type 2 glucoze-sodium transporter inhibitors. The most promising in the treatment of patients with type 2 diabetes and NAFLD are pioglitazone, liraglutide and dapagliflozin.